stavudine

Summary

Summary: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.

Top Publications

  1. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
  2. pmc Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study
    Vichet Phan
    Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia
    PLoS ONE 7:e30647. 2012
  3. pmc Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi
    Joep J van Oosterhout
    Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi
    PLoS ONE 7:e42029. 2012
  4. ncbi Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules
    S D Portsmouth
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    HIV Med 6:185-90. 2005
  5. ncbi Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine
    Somnuek Sungkanuparph
    Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Bangkok 10400, Thailand
    J Clin Virol 41:310-3. 2008
  6. pmc A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects
    Colin N Menezes
    Infectious Diseases Unit, Department of Medicine, Helen Joseph Hospital, University of the Witwatersrand, Johannesburg, South Africa
    BMC Infect Dis 11:244. 2011
  7. ncbi Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda
    Fatu Forna
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 44:456-62. 2007
  8. ncbi Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda
    Johan van Griensven
    Medecins Sans Frontieres, Operational Centre Brussels, Medical Department, Duprestraat 94, 1090 Brussels, Belgium
    Trans R Soc Trop Med Hyg 104:148-53. 2010
  9. ncbi High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda
    Johan van Griensven
    Medecins Sans Frontieres, Kimihurura, Kacyiru, 1361 Kigali, Rwanda
    Trans R Soc Trop Med Hyg 101:793-8. 2007
  10. ncbi Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz
    Katyna Borroto-Esoda
    Gilead Sciences, Inc, 4611 University Drive, Durham, North Carolina 27707, USA
    AIDS Res Hum Retroviruses 23:988-95. 2007

Detail Information

Publications285 found, 100 shown here

  1. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
    ..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
  2. pmc Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study
    Vichet Phan
    Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia
    PLoS ONE 7:e30647. 2012
    Although stavudine (D4T) remains frequently used in low-income countries in Asia, associated long-term toxicity data are scarce...
  3. pmc Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi
    Joep J van Oosterhout
    Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi
    PLoS ONE 7:e42029. 2012
    b>Stavudine is an effective and inexpensive antiretroviral drug, but no longer recommended by WHO for first-line antiretroviral regimens in resource-limited settings due to toxicity concerns...
  4. ncbi Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules
    S D Portsmouth
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    HIV Med 6:185-90. 2005
    ..An expansion in the range of once-daily antiretrovirals is making once-daily therapy possible for persons with HIV infection...
  5. ncbi Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine
    Somnuek Sungkanuparph
    Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Bangkok 10400, Thailand
    J Clin Virol 41:310-3. 2008
    A fixed-dose combination of stavudine, lamivudine, and nevirapine (d4T/3TC/NVP) is extensively used as initial antiretroviral regimen in developing countries...
  6. pmc A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects
    Colin N Menezes
    Infectious Diseases Unit, Department of Medicine, Helen Joseph Hospital, University of the Witwatersrand, Johannesburg, South Africa
    BMC Infect Dis 11:244. 2011
    ..This has brought new challenges which include the effects of stavudine-related toxicities.
  7. ncbi Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda
    Fatu Forna
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 44:456-62. 2007
    ..We evaluated clinical toxicity in HIV-infected persons receiving antiretroviral therapy (ART) in Uganda...
  8. ncbi Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda
    Johan van Griensven
    Medecins Sans Frontieres, Operational Centre Brussels, Medical Department, Duprestraat 94, 1090 Brussels, Belgium
    Trans R Soc Trop Med Hyg 104:148-53. 2010
    This cohort study was conducted to report on the incidence, timing and risk factors for stavudine (d4T)- and nevirapine (NVP)-related severe drug toxicity (requiring substitution) with a generic fixed-dose combination under program ..
  9. ncbi High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda
    Johan van Griensven
    Medecins Sans Frontieres, Kimihurura, Kacyiru, 1361 Kigali, Rwanda
    Trans R Soc Trop Med Hyg 101:793-8. 2007
    ..Of a total of 409 individuals, 370 (90%) were on an ART regimen containing stavudine (d4T), whilst the rest were receiving a zidovudine (AZT)-containing regimen...
  10. ncbi Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz
    Katyna Borroto-Esoda
    Gilead Sciences, Inc, 4611 University Drive, Durham, North Carolina 27707, USA
    AIDS Res Hum Retroviruses 23:988-95. 2007
    ..resistance mutations to the response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV)...
  11. pmc Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus
    Fatih M Uckun
    Parker Hughes Center for Clinical Immunology, St Paul, MN 55113, USA
    BMC Infect Dis 4:1. 2004
    ....
  12. ncbi Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia
    Petros Isaakidis
    Médecins Sans Frontières OCB, Phnom Penh, Cambodia
    J Acquir Immune Defic Syndr 49:48-54. 2008
    To evaluate a treatment strategy of substituting zidovudine (ZDV) for stavudine (d4T)-based highly active antiretroviral therapy (HAART), aimed at preventing d4T-associated toxicity, in a programmatic setting in rural Cambodia.
  13. ncbi Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda
    Barbara Castelnuovo
    Research Department, Infectious Diseases Institute, Makerere University, Kampala Uganda
    J Acquir Immune Defic Syndr 56:59-63. 2011
    ..In resource-limited settings, there are only a few antiretroviral treatment (ART) options. Our objective was to evaluate the reasons for first-line ART changes in resource-limited settings...
  14. ncbi Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa
    Sydney Rosen
    Center for International Health and Development, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 48:334-44. 2008
    Most first-line antiretroviral therapy regimens in Africa include stavudine (d4T), despite the high incidence of toxicities related to it...
  15. ncbi Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression
    Brian A Boyle
    Weill Medical College of Cornell University, New York, New York, USA
    HIV Clin Trials 9:164-76. 2008
    ..In antiretroviral (ARV) therapy, pill burden, dosing frequency, and regimen complexity adversely affect adherence. We sought to evaluate the effect of regimen simplification on maintenance of virologic suppression and treatment adherence...
  16. ncbi Can we predict neuropathy risk before stavudine prescription in a resource-limited setting?
    Jacquita S Affandi
    School of Surgery and Pathology, University of Western Australia, Perth, Australia
    AIDS Res Hum Retroviruses 24:1281-4. 2008
    ..with exposure to inexpensive nucleoside analogue reverse transcriptase inhibitors (NRTIs) [particularly stavudine (d4T)] causes dilemmas in the management of patients with HIV, especially in resource-poor settings...
  17. ncbi Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens
    Kathryn Anastos
    Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 10467, USA
    J Acquir Immune Defic Syndr 45:34-42. 2007
    ..The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described...
  18. ncbi Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    AIDS 15:617-20. 2001
    ..We investigated the incidence of pancreatitis in patients using nucleoside analogues with or without hydroxyurea...
  19. ncbi Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon
    Amandine Cournil
    Institut de Recherche pour le Developpement, University Montpellier 1, Montpellier, France
    Antivir Ther 15:1039-43. 2010
    This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment.
  20. ncbi HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans
    Antonia L Wadley
    Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    J Pain Symptom Manage 41:700-6. 2011
    HIV-associated sensory neuropathy (HIV-SN) is a frequent complication of both HIV and neurotoxic antiretroviral medications such as stavudine.
  21. ncbi Age and height predict neuropathy risk in patients with HIV prescribed stavudine
    C L Cherry
    Burnet Institute, Monash University, and The Alfred Hospital, Melbourne, Australia
    Neurology 73:315-20. 2009
    Sensory neuropathy is a common problem in HIV-infected patients and is the dose-limiting toxicity of stavudine. Affordable methods of predicting neuropathy risk are needed to guide prescribing in countries where some use of stavudine ..
  22. ncbi Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
    F van Leth
    International Antiviral Therapy Evaluation Center, Amsterdam, The Netherlands
    HIV Med 7:347-50. 2006
    ..To assess long-term changes in lipids and lipoproteins concentrations associated with exposure to non-nucleoside reverse transcriptase inhibitors...
  23. pmc Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants
    Jessica M Fogel
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 60:462-5. 2012
    ..antiretroviral treatment regimens in resource-limited settings used in breastfeeding mothers often include stavudine (d4T). Limited data describing d4T concentrations in breast milk are available...
  24. pmc Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa
    Mhairi Maskew
    Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    J Int AIDS Soc 15:13. 2012
    As stavudine remains an important and widely prescribed drug in resource-limited settings, the effect of a reduced dose of stavudine (from 40 mg to 30 mg) on outcomes of highly active antiretroviral therapy (HAART) remains an important ..
  25. ncbi Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, USA
    J Infect Dis 191:1164-8. 2005
    ..after 1 year of treatment with efavirenz and lamivudine plus either tenofovir disoproxil fumarate (n=55) or stavudine (n=45), by use of an HIV RNA assay with a limit of detection of 2.5 copies/mL...
  26. pmc Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia
    Janin Nouhin
    HIV Hepatitis Unit, Institut Pasteur in Cambodia, Phnom Penh, Cambodia Université Paris Diderot, Sorbonne Paris Cité, Paris, France
    PLoS ONE 8:e73744. 2013
    ....
  27. ncbi Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy
    Radhakrishnan Rajesh
    Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India
    Int J Risk Saf Med 23:171-80. 2011
    ..anemia, causality, severity, predictability, preventability and to identify risk factors for zidovudine induced anemia in Indian HIV positive patients in comparision with stavudine based highly active antiretroviral therapy (HAART).
  28. pmc Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa
    Meera Pahuja
    Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Antivir Ther 17:737-43. 2012
    Although recent World Health Organization (WHO) guidelines recommend withdrawing stavudine (d4T) from first-line antiretroviral therapy (ART), it remains commonly used in resource-limited settings...
  29. pmc Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009
    Elvin H Geng
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, 995 Potrero Avenue, San Francisco, CA, USA
    J Int AIDS Soc 14:46. 2011
    ..Regionally representative socio-demographic, laboratory and clinical characteristics of patients accessing ART over time and across sites have not been well described...
  30. pmc Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study
    Sumit Basu
    Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
    Int J Nanomedicine 7:6049-61. 2012
    ..evaluation, and comparison of colloidal gold-loaded, poly(d,l-lactic-co-glycolic acid)-based nanoparticles containing anti-acquired immunodeficiency syndrome drug stavudine and uptake of these nanoparticles by macrophages in vitro.
  31. ncbi Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen
    Wittaya Wangsomboonsiri
    Departments of Medicine, University of Tokyo, Tokyo, Japan
    Clin Infect Dis 50:597-604. 2010
    b>Stavudine-containing antiretroviral regimens are widely used in developing countries...
  32. ncbi A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy
    Wenlong Huang
    Department of Surgery and Cancer, Imperial College London, UK
    Pain 154:560-75. 2013
    ..and is consistently associated with previous exposure to nucleoside reverse transcriptase inhibitors including stavudine (d4T), which is widely used in resource-limited settings...
  33. ncbi Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine
    N Sawawiboon
    Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok noi Bangkok 10700 Thailand
    Int J STD AIDS 23:497-501. 2012
    ..Forty-six (95.8%) children with peripheral or combined LD, and 75 (48.7%) without LD were exposed to stavudine (d4T) for a median duration of 45.9 versus 26.4 months (P = 0.005)...
  34. ncbi Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines
    Alaka Deshpande
    ART Center and Department of Internal Medicine, Sir JJ Hospital, Byculla, Mumbai, India
    AIDS Res Hum Retroviruses 26:343-50. 2010
    ..Numerous crucial DRMs to NRTIs and NNRTIs could be recorded including TAMs of pathway 1 and K65R. According to both algorithms, the accumulation of DRMs may induce resistance to second-line NRTIs including tenofovir...
  35. ncbi Mitochondrial dysfunction in CD4+ lymphocytes from stavudine-treated HIV patients
    Lloyd Einsiedel
    Centre for Virology, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia
    Mitochondrion 10:534-9. 2010
    HIV therapy with nucleoside analogue reverse transcriptase inhibitors (NRTI) such as stavudine remains in widespread use in resource-limited nations due to potent efficacy, convenience of formulation and lack of practical alternatives...
  36. ncbi Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes
    Minakshi Garg
    Department of Pharmaceutical Sciences, Dr Hari Singh Gour University, Sagar, India
    Eur J Pharm Biopharm 67:76-85. 2007
    ..investigation was to reduce the hepatic toxicity, enhance the cellular uptake and alter the pharmacokinetics of stavudine using galactosylated liposomes...
  37. pmc Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade
    Monica Vaccari
    Animal Models and Retroviral Vaccines Section, NCI, NIH, Bethesda, Maryland, USA
    J Virol 86:108-13. 2012
    ..Thus, caution should be used when considering approaches aimed at targeting immune activation during ART...
  38. ncbi Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine
    Dale J Kempf
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, USA
    J Infect Dis 189:51-60. 2004
    ..randomized, phase 3 study that compared lopinavir/ritonavir with nelfinavir, each coadministered with stavudine and lamivudine, in 653 antiretroviral therapy-naive human immunodeficiency virus (HIV) type 1-infected subjects...
  39. pmc R964C mutation of DNA polymerase gamma imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity
    Christopher M Bailey
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    Antimicrob Agents Chemother 53:2610-2. 2009
    The R964C mutation of human DNA polymerase gamma was recently linked to stavudine (d4T)-mediated mitochondrial toxicity...
  40. pmc beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL
    Mingjie Zhang
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Retrovirology 5:82. 2008
    ..Recent work suggests there are gender effects in HIV/AIDS progression. Here we ask whether the sex steroid hormone beta-estradiol affects the replication of HIV-1 or the efficacy of a common anti-retroviral drug, Stavudine (D4T).
  41. ncbi Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon
    Christian Laurent
    Institut de Recherche pour le Developpement, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS Res Hum Retroviruses 24:393-9. 2008
    ..of two major first-line regimens used in resource-limited settings, namely zidovudine-lamivudine-nevirapine and stavudine-lamivudine-nevirapine...
  42. ncbi Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 200:687-97. 2009
    ....
  43. ncbi Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia
    Laurent Ferradini
    Epicentre, Paris, France
    AIDS 21:2293-301. 2007
    ..We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia...
  44. pmc Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda
    N Sacktor
    Department of Neurology, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, USA
    Neurology 72:165-70. 2009
    ..Coformulated generic drugs, which include stavudine, are the most common regimens to treat HIV infection in Uganda and many other parts of Africa.
  45. ncbi Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine
    Grace A McComsey
    Rainbow Babies and Children s Hospital bCase School of Medicine Center for AIDS Research, Cleveland, Ohio, USA
    AIDS 19:15-23. 2005
    To determine if stavudine (alpha4T)-associated mitochondrial toxicity could be reversed by substitution with another nucleoside reverse transcriptase inhibitor...
  46. ncbi Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes
    Say Viengchareun
    INSERM, U693, Faculte de Medecine Paris Sud, Le Kremlin Bicetre, France
    Antivir Ther 12:919-29. 2007
    ..To evaluate the mechanisms of mitochondrial toxicity associated with antiretroviral treatment...
  47. ncbi Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program
    Emmanuel O Idigbe
    Clinical Research Centre, Nigerian Institute of Medical Research, Federal Ministry of Health, Lagos
    J Acquir Immune Defic Syndr 40:65-9. 2005
    To evaluate treatment outcome in the first 12 months among HIV-positive patients managed with a combination of nevirapine + stavudine + lamivudine under the current national antiretroviral (ARV) program in Nigeria.
  48. ncbi The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients
    Ana Milinkovic
    Infectious Diseases Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Antivir Ther 12:407-15. 2007
    b>Stavudine (d4T)-containing regimens are associated with a potential for lipoatrophy and dyslipidaemia...
  49. ncbi Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails
    Somnuek Sungkanuparph
    Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Clin Infect Dis 44:447-52. 2007
    A fixed-dose combination of stavudine, lamivudine, and nevirapine is extensively used as an antiretroviral regimen in developing countries because of its affordability...
  50. ncbi Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy
    Linda Aurpibul
    Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand
    Antivir Ther 12:1247-54. 2007
    ..Its long-term effects have not been clearly evaluated. The objective of this study was to estimate the prevalence of lipodystrophy (LD) and other metabolic changes in HIV-infected children receiving HAART...
  51. ncbi Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine
    S M Arpadi
    St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York City, New York, USA
    J Acquir Immune Defic Syndr 27:30-4. 2001
    ..LD was associated with use of protease inhibitors or stavudine, (odds ratio [OR], 7.0, 95% confidence interval [CI], 1.1-45.2, p =.04; OR, 9.0, 95% CI, 1.4-59.8, p =...
  52. pmc HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa
    Christopher J Hoffmann
    Aurum Institute for Health Research, Johannesburg, South Africa
    AIDS 23:1784-6. 2009
    In 2007, the WHO recommended a maximum stavudine dose of 30 mg...
  53. ncbi Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study
    Grace A McComsey
    Case Western Reserve, Cleveland, Ohio, USA
    Clin Infect Dis 38:263-70. 2004
    b>Stavudine use is a contributing factor for lipoatrophy, whereas use of abacavir or zidovudine is less likely to cause this complication...
  54. ncbi A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity
    P N Kumar
    Georgetown University Medical Center, Washington, DC 20007, USA
    HIV Med 7:85-98. 2006
    ..regimens of Trizivir (abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg triple nucleoside tablet; TZV), Combivir (lamivudine 150 mg/zidovudine 300 mg combination tablet; COM)+nelfinavir (NFV), and stavudine (d4 T)+lamivudine (3TC)+NFV.
  55. pmc Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy
    Daniel J Westreich
    Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
    Clin Infect Dis 48:1617-23. 2009
    Treatment for tuberculosis (TB) is common among individuals receiving stavudine-containing highly active antiretroviral therapy (HAART), but the effect of TB treatment on stavudine toxicity has received little attention...
  56. ncbi Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics
    Minakshi Garg
    Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr Hari Singh Gour University, Sagar 470003, India
    J Pharm Pharmacol 58:605-16. 2006
    ..b>Stavudine-loaded mannosylated liposomal formulations were developed for targeting to HIV-infected cells...
  57. ncbi Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa
    David Stead
    GF Jooste Hospital, Cape Town, South Africa
    Antivir Ther 13:937-43. 2008
    In the public sector antiretroviral therapy (ART) programme in South Africa the standardized first-line regimen includes stavudine (d4T). Severe symptomatic hyperlactataemia (SHL) is a potentially life-threatening complication of d4T.
  58. ncbi Disease progression in HIV-infected patients treated with stavudine vs. zidovudine
    Amy C Justice
    Yale University, New Haven, CT, USA
    J Clin Epidemiol 57:89-97. 2004
    This prospective, observational study compared disease progression and death in HIV-1 patients treated with stavudine vs. zidovudine in the Collaborations in HIV Outcomes Research/U.S. (CHORUS) cohort.
  59. ncbi Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV
    D Rey
    Clin Infect Dis 34:418-9. 2002
  60. ncbi Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection
    Maria Gracia Mateo
    Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Univeristat Autònoma de Barcelona, Av Sant Antoni Mª Claret, 167, 08025 Barcelona, Spain
    Expert Opin Drug Saf 11:473-85. 2012
    The lamivudine (3TC) + stavudine (d4T) combination is still widely used as part of first-line therapy for HIV-1-infected patients in low-resource countries...
  61. ncbi The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
    F Raffi
    Department of Infectious Diseases, University Hospital Nantes, France
    Antivir Ther 5:267-72. 2000
    ..efficacy of the triple regimen containing nevirapine (once or twice daily), didanosine (once daily) and stavudine, in antiretroviral-naive patients infected with HIV-1, was evaluated in an open-label, prospective, non-..
  62. ncbi Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor
    Pere Domingo
    Department of Internal Medicine Infectious Diseases Unit Biochemistry and Endocrinology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Antivir Ther 8:223-31. 2003
    ....
  63. pmc In silico study supports the efficacy of a reduced dose regimen for stavudine
    Selwyn J Hurwitz
    Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
    Antiviral Res 92:372-7. 2011
    b>Stavudine (d4T) is used extensively as part of HAART in resource poor settings, despite its toxicities...
  64. ncbi Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats
    Zheng Yang
    Department of Pharmaceutics, University of Minnesota, 308 Harvard St SE, Minneapolis, MN 55455, USA
    J Pharm Sci 94:1577-88. 2005
    Intranasal (IN) administration as a potential route of enhancing brain delivery of stavudine (d4T) was investigated in rats using microdialysis as a sampling technique. Sprague-Dawley rats were divided into two groups (n = 7 per group)...
  65. ncbi Biowaiver monographs for immediate-release solid oral dosage forms: stavudine
    Arthur L L Silva
    Brazilian Health Surveillance Agency, ANVISA, Division of Bioequivalence, Brasilia, Brazil
    J Pharm Sci 101:10-6. 2012
    ..vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing stavudine (d4T) are reviewed...
  66. ncbi Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians
    Joep J G van Oosterhout
    University of Malawi College of Medicine, Department of Medicine, Malawi
    Antivir Ther 12:515-21. 2007
    ..Starting antiretroviral therapy early during tuberculosis treatment may improve outcome but problems often arise with drug interactions, adherence, toxicity and immune reconstitution disease (IRD)...
  67. pmc Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment
    Thong Phe
    Department of Infectious Diseases, Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia
    PLoS ONE 8:e60206. 2013
    ..Some studies suggested weight-adjusted AZT dosing as a way to reduce toxicity. We analyzed the risk factors associated with AZT-induced anemia in a cohort using AZT as substitution for stavudine (D4T).
  68. ncbi Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy
    L Aurpibul
    Research Institute for Health Sciences, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    HIV Med 9:317-21. 2008
    In resource-limited countries, stavudine (d4T) is commonly used as part of the initial highly active antiretroviral therapy (HAART) regimen...
  69. pmc Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study
    Kavindhran Velen
    The Aurum Institute, Johannesburg, South Africa
    PLoS ONE 8:e64459. 2013
    ..routine workplace and community-based ART cohort in South Africa, we assessed single drug substitution, HIV RNA suppression, CD4 count increase, loss-from-care, and mortality between TDF, stavudine (d4T) 30 mg dose, and zidovudine (AZT).
  70. ncbi Metabolism of stavudine-5'-[p-bromophenyl methoxyalaninyl phosphate], stampidine, in mice, dogs, and cats
    Chun Lin Chen
    Drug Discovery Program, Parker Hughes Institute, St Paul, Minnesota 55113, USA
    Drug Metab Dispos 30:1523-31. 2002
    ..These findings encourage the further development of this new antiviral agent for possible clinical use in human immunodeficiency virus-infected patients...
  71. ncbi Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study
    F Garcia
    Infectious Diseases Unit, Institut d Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic, Faculty of Medicine, University of Barcelona, Spain
    AIDS 14:2485-94. 2000
    To evaluate the safety and effectiveness of once-daily didanosine and nevirapine plus twice-daily stavudine versus twice-daily administration of all three drugs.
  72. ncbi The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study
    Colette J Smith
    Royal Free and University College Medical School, London, UK
    AIDS 22:47-56. 2008
    This study investigated the incidence of pancreatitis and its association with antiretroviral therapy (ART), focussing on stavudine and didanosine.
  73. pmc The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes
    Lachlan R Gray
    Centre for Virology, Burnet Institute, Melbourne, Victoria, Australia
    PLoS ONE 8:e62196. 2013
    ..ARVs tested were the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir (ABC), lamivudine (3TC), stavudine (d4T) and zidovudine (ZDV), the non-NRTIs efavirenz (EFV), etravirine (ETR) and nevirapine (NVP), and the ..
  74. ncbi Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting
    N Kumarasamy
    YRG Centre for AIDS Research and Education, Voluntary Health Services, Taramani, Chennai 600113, India
    Int J Infect Dis 13:e360-4. 2009
    To describe the safe substitution with zidovudine (AZT) among South Indian HIV-infected patients who were initiated with stavudine (d4T)-containing highly active antiretroviral therapy (HAART) due to anemia.
  75. ncbi [Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions]
    Enric Pedrol
    Unitat de Malalties Infeccioses VIH, Hospital General de Granollers, Granollers, Barcelona, Espana
    Med Clin (Barc) 129:361-5. 2007
    b>Stavudine (d4T) has shown a favourable short and long-term tolerability profile. Nevertheless, its usage is currently decreasing due to some safety concerns. We aimed to evaluate the efficacy and safety of d4T low-dose-based regimens.
  76. ncbi Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy
    Mark Nelson
    Imperial College, Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    AIDS 22:1374-6. 2008
    We report a case of the nucleoside reverse transcriptase inhibitors, stavudine and lamivudine inducing Fanconi syndrome in a patient...
  77. pmc Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection
    S Kaul
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543 4000, USA
    Antimicrob Agents Chemother 45:758-63. 2001
    The results of the development of dosing guidelines for stavudine in human immunodeficiency virus (HIV)-infected children are summarized...
  78. pmc Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex
    C M Horton
    Antiinfective Pharmacology Research Unit, University of Rhode Island College of Pharmacy, Roger Williams Medical Center, Providence 02908, USA
    Antimicrob Agents Chemother 39:2309-15. 1995
    The population pharmacokinetics and bioavailability of oral stavudine (d4T; 2',3'-dideoxy-3'-deoxythymidine) was determined in 81 patients with AIDS or AIDS-related complex (ARC) enrolled in phase I and phase I/II dose-ranging trials...
  79. pmc HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya
    H N Kim
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    J Viral Hepat 18:e447-52. 2011
    ..389 Kenyan HIV-infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty-seven (6...
  80. ncbi Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine
    Carme Vidal
    Microbiology Laboratory, Institut Clínic de Infeccions i Immunologia, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    Antivir Ther 7:283-7. 2002
    ..of resistance in a group of early-stage antiretroviral-naive patients failing initial therapy with didanosine, stavudine and nevirapine...
  81. ncbi Production & stability of stavudine solid lipid nanoparticles--from lab to industrial scale
    R Shegokar
    CU Shah College of Pharmacy, SNDT Women s University, Mumbai 400049, India
    Int J Pharm 416:461-70. 2011
    The production of stavudine-loaded solid lipid nanoparticles (SLN) for intravenous injection was scaled up from lab scale (40 g) to medium scale (10 kg) and large scale (20/60 kg)...
  82. pmc Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy
    Pere Domingo
    Infectious Diseases Unit, Hospital de Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antimicrob Agents Chemother 55:1428-35. 2011
    The antiviral activity and toxicity of stavudine (d4T) depend on its triphosphate metabolite, stavudine triphosphate (d4T-TP). Therefore, modifications in intracellular levels of d4T-TP may change the toxicity profile of stavudine...
  83. pmc Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients
    Daria Trabattoni
    Cattedra di Immunologia, Universita di Milano, DISP, LITA Vialba, Milan, Italy
    Clin Diagn Lab Immunol 9:1114-8. 2002
    ..Analysis of the virologic and immunomodulatory effects of an association of efavirenz (EFV), nelfinavir (NFV), and stavudine (d4T) was performed in 18 human immunodeficiency virus (HIV)-infected and highly active antiretroviral therapy (..
  84. ncbi Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy
    Linda Aurpibul
    Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand
    Pediatr Infect Dis J 31:384-8. 2012
    Substitution of stavudine with zidovudine may lead to recovery from lipodystrophy (LD) in HIV-infected children.
  85. ncbi Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate
    Adrian S Ray
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520 8066, USA
    Biochemistry 41:5150-62. 2002
    ..This compound shows promise as a potent antiviral especially with the drug resistant M184V HIV-1 RT that is so often encountered in a clinical setting...
  86. ncbi Synthesis and transdermal penetration of stavudine-5'-esters
    Estée Marie Holmes
    Pharmaceutical Chemistry, Unit for Drug Research and Development, North West University, Potchefstroom 2520, South Africa
    Med Chem 6:271-6. 2010
    The aim of this study was to investigate the effects of different ester groups in position 5' of stavudine on the transdermal penetration with and without the use of Pheroid™ as the delivery system...
  87. ncbi Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations
    L Sarmati
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 65:631-6. 2001
    ..of AZT resistance mutations in AZT-naive patients, 56 HIV-1 seropositive patients treated for 18 months with stavudine/lamivudine (27 patients) or AZT/lamivudine (29 patients) were studied...
  88. pmc Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand
    BMC Infect Dis 8:136. 2008
    To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings.
  89. ncbi Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study
    Grace McComsey
    Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA
    Clin Infect Dis 48:1323-6. 2009
    ..virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine...
  90. ncbi In vivo antagonism with zidovudine plus stavudine combination therapy
    D V Havlir
    1University of California, San Diego, 2San Diego VA Medical Center, San Diego, California, USA
    J Infect Dis 182:321-5. 2000
    Human immunodeficiency virus (HIV)-infected subjects receiving zidovudine were randomized either to add stavudine (d4T) or didanosine (ddI) to their current regimen or to switch to ddI or d4T monotherapy...
  91. ncbi Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz
    Alessandro Viganò
    Department of Paediatrics, L Sacco Hospital, University of Milan, Italy
    Antivir Ther 12:297-302. 2007
    An antiretroviral regimen based on lamivudine+stavudine+protease inhibitor impairs peripheral fat accrual in HIV-infected children and adolescents...
  92. pmc Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'Ivoire
    Albert Minga
    Programme PAC CI, Abidjan, Cote d Ivoire
    AIDS Res Hum Retroviruses 26:991-5. 2010
    b>Stavudine is no longer recommended for use in first-line antiretroviral therapy (ART), but it remains in high demand worldwide because it is affordable...
  93. ncbi Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice
    J L Yozviak
    Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, USA
    HIV Clin Trials 2:474-6. 2001
    ..This retrospective chart review examines the effectiveness, tolerability, and convenience of a nevirapine (NVP), stavudine (d4T), and lamivudine (3TC)-containing regimen in an urban HIV clinical practice...
  94. pmc Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients
    C Herzmann
    EPIMED GmbH, Vivantes Auguste Viktoria Klinikum, Berlin, Germany
    Antimicrob Agents Chemother 49:2828-33. 2005
    ..RCV was administered once a day orally for 14 days at doses of 200, 400, or 600 mg in combination with stavudine and efavirenz to HIV-1-infected treatment-naïve male volunteers in a phase Ib/IIa study...
  95. ncbi Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine
    Raph L Hamers
    Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
    Antivir Ther 16:115-8. 2011
    ..multi-NRTI-resistance Q151M complex, K65R, M184I and Y181I, after using standard first-line generic fixed-dose stavudine, lamivudine and nevirapine (Triomune™) for 36 months...
  96. ncbi Relation of stavudine discontinuation to anthropometric changes among HIV-infected women
    Phyllis C Tien
    Department of Medicine, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    J Acquir Immune Defic Syndr 44:43-8. 2007
    To characterize changes in regional anthropometry associated with stavudine exposure and discontinuation.
  97. pmc In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice
    Fatih M Uckun
    Drug Discovery Program, Departments of Virology, Immunology, Pathology, Pharmaceutical Sciences, and Chemistry, Parker Hughes Institute, St Paul, and Parker Hughes Center for Clinical Immunology, Roseville, Minnesota 55113, USA
    Antimicrob Agents Chemother 46:3428-36. 2002
    We have evaluated the clinical potential of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate(stampidine [STAMP]), a novel aryl phosphate derivative of stavudine, as a new anti-human immunodeficiency virus (anti-HIV) agent, by ..
  98. ncbi Mitochondrial DNA base excision repair and mitochondrial DNA mutation in human hepatic HuH-7 cells exposed to stavudine
    Yasong Wu
    HIV AIDS Research Center, Beijing You An Hospital, Capital Medical University, Beijing 100069, China
    Mutat Res 664:28-38. 2009
    ..that mitochondrial oxidative stress leads to changes in the balance between mtDNA repair and mutation following stavudine (d4T) treatment...
  99. ncbi Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
    ..relevant drug interactions between ritonavir-boosted elvitegravir (EVG/r) and the nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine (ZDV), didanosine (ddI), stavudine (d4T), or abacavir (ABC) upon coadministration.
  100. ncbi Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy
    Miriam Casula
    International Antiviral Therapy Evaluation Center, University of Amsterdam, The Netherlands
    J Infect Dis 192:1794-800. 2005
    ..Mitochondrial DNA (mtDNA) in peripheral blood mononuclear cells (PBMCs) has been suggested as a potential marker of mitochondrial toxicity associated with nucleoside analogue reverse-transcriptase inhibitor-containing therapy...
  101. pmc A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand
    Nirun Vanprapar
    Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Pediatr Infect Dis J 29:940-4. 2010
    ..the relative bioavailability, safety, and therapeutic adequacy of a novel chewable pediatric FDC tablet of stavudine (7 mg), lamivudine (30 mg), and nevirapine (50 mg), referred to as GPO-VIR S7, and compared it with the ..

Research Grants62

  1. HIV and Global Drug Therapies: Peripheral Neuropathy Complications and Mechanisms
    Cecilia M Shikuma; Fiscal Year: 2012
    ..underlying HIV-SN in individuals initiating HAART;how the pathogenesis and interactions may be altered by stavudine (d4T), a neuropathic anitretroviral (ARV) medication;and whether irreparable damage to the nerves can occur with ..
  2. HIV associated Lipodystrophy Syndrome in Children: Role of nutrition, ART &Genes
    Soumya Swaminathan; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): An increasing number of HIV infected children are being started on stavudine containing antiretroviral treatment regimens in India...
  3. Biochemical Pharmacology of Anti-HIV Compounds
    Yung Chi Cheng; Fiscal Year: 2013
    ..4'- Ed4T has much better therapeutic index in cell culture than either zidovudine (AZT) or stavudine (D4T)...
  4. Nucleoside Transporters In HAART Mitochondrial Toxicity
    John Buolamwini; Fiscal Year: 2006
    ..These nucleoside drugs, including zidovudine (AZT), stavudine (d4T), didanosine (DDI), zalcitabine (DDC) and lamivudine (3TC) are believed to cause mitochondria! depletion to ..
  5. ART PHARMACOKINETICS IN SEVERELY MALNOURISHED HIV-INFECTED CHILDREN
    Ericka Hayes; Fiscal Year: 2009
    ..Area under the curve pharmacokinetic measurements will be done for stavudine, lamivudine and nevirapine after 2 and 8 weeks of HAART...
  6. HIV Therapy & Interruption RCT in Resource Poor Clinic
    Luis J Montaner; Fiscal Year: 2010
    ..viral suppression to <50 copies/ml during a 24 week "run-in" period on lopinavir/ritonavir, lamivudine, stavudine to include a complete vaccination series against rabies from week 16 to 22 (de novo antigen) before ..
  7. HIV Therapy & Interruption RCT in Resource Poor Clinic
    Luis Montaner; Fiscal Year: 2004
    ..viral suppression to <50 copies/ml during a 24 week "run-in" period on lopinavir/ritonavir, lamivudine, stavudine to include a complete vaccination series against rabies from week 16 to 22 (de novo antigen) before ..
  8. Stampidine: A Novel Broad-Spectrum Antiviral Agent
    Taracad Venkatachalam; Fiscal Year: 2003
    Stampidine [STAMP], [STV-5'-[p-bromophenyl methoxyalaninyl phosphate] is a novel aryl phosphate derivative of Stavudine (STV/d4T), a pyrimidine nucleoside analogue used in the treatment of HIV infection...
  9. Metabolic and Nutritional Effects of ART in Children
    Meera Chhagan; Fiscal Year: 2009
    ..These guidelines recommend stavudine, lamivudine and lopinavir/ritonavir for children less than 3 years, or stavudine, lamivudine and efavirenz if ..
  10. Bioactive Compounds from Acylnitroso Cycloadducts
    Marvin Miller; Fiscal Year: 2006
    ..inhibitors, benzodiazepines, diazepines, carbocyclic nucleosides and analogs (aristeromycin, carbavir, abacavir, stavudine, carbocyclic oxanosine, and their nor analogs, carbocyclic forms of polyoxins, sinefungin, nucleoside Q, ..
  11. Mutagenesis of Single/Combined NRTI Drugs in Human Cells
    Vernon Walker; Fiscal Year: 2004
    ..will be performed to measure (by specific RIAs) DNA incorporation of zidovudine (AZT), lamivudine (3TC), and/or stavudine (d4T), and to measure and characterize the mutagenic response at the HPRT and APRT loci of AZH-1cells and the ..
  12. DOT-HARRT for HIV-Infected South African Adults
    Jean Nachega; Fiscal Year: 2010
    ..300 patients will be assigned to either peer-DOT-HAART or self-administration of a twice daily combination of Stavudine, Lamivudine and Efavirenz for 24 months...
  13. Formulation of dosage of the anti-HIV agent, DDE113
    Darin DuMez; Fiscal Year: 2005
    ..This nucleoside analog is significantly more potent than stavudine and AZT for many primary clinical human HIV isolates...
  14. Uridine Supplementation for HIV lipoatrophy
    Grace McComsey; Fiscal Year: 2007
    ..On-study subjects will continue to be followed per study protocol for a total of 12 months. The last 6 months of the grant will be dedicated to processing of samples and analysis of all data. [unreadable] [unreadable]..
  15. Role of Mitochondria in HIV Lipoatrophy
    Grace McComsey; Fiscal Year: 2009
    ..abstract_text> ..
  16. Metabolic Consequences of Thymidine Sparing Regimens
    Grace A McComsey; Fiscal Year: 2010
    ..at the top of each printed page and each continuation page. RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description, ..
  17. Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    Mitchell Goldman; Fiscal Year: 2006
    ..abstract_text> ..
  18. Vanadocenes as a New Class of Spermicidal Drugs
    OSMOND D CRUZ; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  19. Stampidine: A Novel Broad-Spectrum Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ..transmission of HIV without affecting fertility, we have synthesized a series of phenyl phosphate derivatives of stavudine (STV/d4T) and identified stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) [Stampidine or STAMP], as the ..
  20. Phase II SBIR: WHI-07: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ....
  21. PHI 346: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Following successful completion of the Phase I in vivo efficacy studies, gel formulation of PHI-346 will be further explored as a vaginal dual-function microbicide in Phase II. ..
  22. FLP-102: Rationally Engineered Antiviral Protein
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
  23. METVAN: A Novel Anticancer Agent
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The knowledge gained from these studies described under Specific Aims 1-2 is expected to facilitate the design of innovative treatment regimens employing METVAN for metastatic breast cancer and brain tumor patients. ..
  24. NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITY
    OSMOND D CRUZ; Fiscal Year: 2001
    ..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
  25. PHI-443: Novel Non-Spermicidal Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Specific Aims 1 and 2 may provide the foundation for the clinical development of PHI-443 in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
  26. CARDIOMYOPATHY IN AIDS
    William Lewis; Fiscal Year: 2009
    ..HYPOTHESIS 4: mtDNA depletion (from any above) causes or results from oxidative stress. Antioxidants ameliorate oxidative stress from NRTIs by decreasing oxidation of mtDNA. ..
  27. CARDIAC DYSFUNCTION, AIDS AND COCAINE
    William Lewis; Fiscal Year: 2003
    ..Immuno-LM and immuno-TEM identify cellular and subcellular alterations. ..
  28. Acquired mtDNA depletion and nucleoside reverse transciptase inhibitors
    William Lewis; Fiscal Year: 2010
    ..Survival with HIV/AIDS improved because of pyrimidine NRTIs like zidovudine (AZT) and stavudine (d4T), but NRTI mitochondrial toxicity limits therapy and mani- fests as mtDNA depletion and organ dysfunction...
  29. Hepatic mitochondrial oxidative stress, AIDS and alcohol
    William Lewis; Fiscal Year: 2005
    ..Biochemical, molecular and pathological changes (above) are ameliorated. This serves as a "proof of principle". ..
  30. AIDS and Alcohol and Cardiomyopathy
    William Lewis; Fiscal Year: 2005
    ..Myofibrillar, nuclear and mitochondrial volumes are analyzed quantitatively (by transmission electron microscopy [TEM]). Volume fractions of extracellular matrix and of myocytes are determined morphometrically (light and TEM). ..
  31. Nucleoside analogs, mitochondria and AIDS cardiomyopathy
    William Lewis; Fiscal Year: 2006
    ..AIM 2: to define CM from HAART microscopically and ultrastructurally using morphometric methods. AIM 3: to define cardiac performance in CM from HAART echocardiographically and using Langendorff preparations. ..
  32. PROTEASE INHIBITOR RELATED ATHEROSCLEROSIS IN HIV
    Andrew Carr; Fiscal Year: 2005
    ....
  33. CNS Viral Dynamics and Cellular Immunity During AIDS
    David Haas; Fiscal Year: 2009
    ..Characterizing these relationships will expand our knowledge regarding key events that lead to AIDS dementia, and may suggest novel approaches to other immunologic or viral-mediated diseases that affect the brain. ..
  34. VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
    David Haas; Fiscal Year: 2006
    ..The proposed ACTU will not only enroll patients into ACTG clinical trials, but will provide the ACTG the ability to address important questions concerning AIDS treatment and pathogenesis. ..
  35. Predictors of Immunologic Long-term Non-Progression in Children with HIV
    Jintanat Ananworanich; Fiscal Year: 2010
    ..This will be important in deciding when to treat children with antiretroviral therapy. ..
  36. Non-nucleoside Reverse Transcriptive Hypersensitivity
    Nancy Shulman; Fiscal Year: 2006
    ....
  37. HAART associated body shape & metabolic changes in India
    Suneeta Saghayam; Fiscal Year: 2009
    ..Metabolic changes will be evaluated every 6 months by fasting lipids, insulin, glucose and 2hr glucose (yearly). Fasting lactate and C-reactive protein will also be measured every 6 months. ..
  38. Optimizing strategies for universal HIV testing
    Rochelle P Walensky; Fiscal Year: 2010
    ..The scientific basis for early detection of HIV infection and aggressive linkage to care has been successfully laid. The challenge now is to identify effective, affordable, and cost-effective implementation mechanisms. ..
  39. TrkB.T1 as a Genetic Disease Modifier of Muscular Dystrophy
    CHRISTOPHER WILLIAM WARD; Fiscal Year: 2010
    ..This study will try to figure out why these two molecules may be possible therapeutic targets. Our goal is to prevent, improve, or restore muscle function in patients with muscular dystrophy. ..
  40. DELETION MUTAGENESIS WITHIN NONCODING SEGMENTS OF HIV1
    Mark Wainberg; Fiscal Year: 2001
    ..6. To determine whether these attenuated SIV constructs may protect against subsequent challenge with virulent forms of SIV and SIV/HIV hybrids. ..
  41. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel R Kuritzkes; Fiscal Year: 2010
    ..This research program provides a framework within which the applicant can mentor beginning clinical investigators in patient-oriented research focused on critical issues in HIV-1 medicine. ..
  42. K24 MID-CAREER CLINICAL INVESTIGATOR AWARD
    John Bartlett; Fiscal Year: 2004
    ..These mentorship activities are strongly supported by leadership of the Department of Medicine and the Division of Infectious Diseases, and an AIDS Training Grant, which provides financial support for young investigators. ..
  43. HIV-1 resistance to nucleoside analogues
    Daniel Kuritzkes; Fiscal Year: 2004
    ..Better understanding of the virologic, genetic, and biochemical aspects of AZT/3TC dual resistance will help direct therapy and may lead to better therapeutic strategies in the future. ..
  44. The Impact of HLA in Children Receiving HAART
    Akihiko Saitoh; Fiscal Year: 2008
    ..This research will also suggest modes of pathogenesis that can lead to the development of vaccine strategies. ..
  45. Design and Testing of a Parechovirus Vaccine Vector
    Paul Krogstad; Fiscal Year: 2005
    ..We propose to construct and complete the initial in vitro testing of a parechovirus based vaccine vector, based on strategies already employed in the successful construction of enteroviral vectors. ..
  46. Integrated Human Research Subjects Protection Project
    Ross McKinney; Fiscal Year: 2003
    ..abstract_text> ..
  47. Mitochondria And Metabolic Complications Of HIV
    Pablo Tebas; Fiscal Year: 2006
    ..In order to do this we will use a NASBA based assay to measure the mitochondrial DNA and RNA content in PBMCs, and use 2000 specimens collected longitudinally in 3 large ACTG studies. ..
  48. HORMONAL REGULATORS OF MUSCLE AND METABOLISM IN AGING
    Fred Sattler; Fiscal Year: 2005
    ..The results should also provide valuable information for future testing of new, novel treatment strategies, which are more tolerable and convenient than parenteral therapies for age associated sarcopenia. ..
  49. Tulane/LSU HIV/AIDS Clinical Trials Networks Unit
    Russell Van Dyke; Fiscal Year: 2007
    ..unreadable] [unreadable] ADMINISTRATIVE COMPONENT: [unreadable] [unreadable] [unreadable]..
  50. Antiretroviral Pharmacology/Lactating Mother/Infants
    Mark Mirochnick; Fiscal Year: 2006
    ..This information is needed for the safe and effective use of antiretrovirals in nursing women, and will pioneer a novel approach to the study of breast milk drug transfer. ..
  51. Cellular Immunology of Enterovirus Infection
    Paul Krogstad; Fiscal Year: 2007
    ..These studies will provide a foundation for further studies of host-pathogen relationships in picornavirus disease and the potential utility of picornaviruses as enterally delivered vaccine vectors. [unreadable] [unreadable] [unreadable]..
  52. Simulating Mitochondrial Toxicity of Nucleoside Analogs
    David Samuels; Fiscal Year: 2007
    ..The results of these simulations will be compared with experiments conducted by our collaborator, and will be used to interpret these experiments. [unreadable] [unreadable] [unreadable]..
  53. Fitness of Enfuvirtide-(T-20)-Resistant HIV-1
    Daniel Kuritzkes; Fiscal Year: 2006
    ..Results of these studies will provide a deeper understanding of the molecular, virologic, and clinical consequences ofT-20 resistance, and may help guide the use of T-20 in salvage therapy. ..
  54. RECENT ADVANCES IN AIDS AND HIV RESEARCH
    Michael Saag; Fiscal Year: 2007
    ..CME credit for attending physicians will be provided. ..
  55. International Clinical Trials Unit
    John Bartlett; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  56. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2007
    ..abstract_text> ..
  57. Safety Pharmacokinetics & Efficacy of Artemether & Lumefantrine in Pregnant Women
    Mark Mirochnick; Fiscal Year: 2008
    ..The data from this planned study will provide the information needed to ensure that pregnant women receive the appropriate doses of these anti-malaria drugs. [unreadable] [unreadable] [unreadable]..
  58. Clinical Significance of HIV Replication Fitness
    Lisa Demeter; Fiscal Year: 2008
    ..If these studies are successful, they could identify tests that could help predict clinical outcomes for HIV-infected patients. ..
  59. Alcohol and HIV Progression in the Hopkins HIV Cohort
    Richard Moore; Fiscal Year: 2005
    ..We believe that our research will yield valuable results to better understand the relationship between alcohol use and HIV/AIDS. ..